• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Asia-Pacific Journal Of Clinical Oncology

    Asia-Pacific Journal Of Clinical Oncology

    JournalISSN 1743-7555eISSN 1743-7563中科院 医学 4区

    年发文量

    研究主题

    论文(169012)

    排序
    1Risk Factor Profiles May Differ Between Younger‐Onset and Late‐Onset Colorectal Cancer: an Exploratory Analysis of Individual and Cumulative Risk Factors among the Prostate, Lung, Colorectal and Ovarian Cohort
    Lucas Wigston, Muktar Ahmed,Zegeye Abebe,Stephen J. Pandol, Yohannes Adama Melaku,Savio George Barreto

    ABSTRACT Background Rates of young‐onset colorectal cancer (CRC) are on the rise globally. Despite this growing burden, the drivers of young‐onset adult CRC remain largely unknown. Aims This study aimed to compare risk factor profiles between younger‐onset and late‐onset CRC to evaluate differences in their risk factor profiles. Methods The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial dataset, comprising ∼155,000 US participants including 1219 CRC cases, was analysed. Participants were stratified by age (≤59 vs. ≥60 years). Associations of demographic, clinical and behavioural risk factors with CRC were computed using multivariable Cox regression with the multiplicative interaction of exposures. Reduced rank regression was used to derive dietary patterns (DPs). Results Among the ≤59‐year cohort, no individual risk factor (excluding age) was independently associated with the risk of CRC. However, the multiplicative effect of hypertension and smoking had a nominal association with younger‐onset CRC ( p = 0.047). In contrast, in the ≥60‐year cohort, individual (sex, body mass index, diabetes and alcohol) as well as combinations of risk factors were associated with CRC. Significant DPs appeared exclusively to impact the risk of CRC in the ≥60‐year cohort. However, no interactions remained significant following correction for multiple testing; findings should be interpreted as hypothesis‐generating. Conclusions These findings suggest that the drivers of CRC in younger individuals may be different from their older counterparts. These exploratory findings offer novel insight into CRC risk in the young and highlight the need to reconsider interactions between CRC risk factors.

    2026
    引用
    AI阅读
    加入学术空间
    2Transarterial Chemoembolization and Chemo-Immunoembolization in Locally Advanced Rectal Cancer: an Updated Systematic Review.
    Omar Abu Saadeh, H. Temperley, N. O'Sullivan, B. M. Mac Curtain, Kevin P. Sheahan, Julian Soares, M. Kelly, S. Warrier, Zi Ng

    Locally advanced rectal cancer (LARC) often requires aggressive multimodal therapy, yet pathological complete response (pCR) to standard chemoradiotherapy remains low. Transarterial chemoembolization (TACE) enables targeted locoregional delivery of chemotherapy to tumor-feeding arteries, and its recent extension, chemo-immunoembolization, permits intraarterial delivery of immune checkpoint inhibitors. This updated systematic review searched MEDLINE, EMBASE, and Web of Science from inception to June 2026 for studies of TACE or transcatheter rectal arterial chemoembolization (TRACE) in LARC, with quality appraised using the Newcastle-Ottawa Scale. Nine studies encompassing 822 patients, 582 of whom received TACE or TRACE, were included, predominantly from China; one further trial is ongoing. pCR rates ranged from 10% to 44.74%. In comparative studies, TRACE with oxaliplatin was associated with lower tumor regression grade 3 (TRG3) rates, reaching significance in the largest comparison, and with a survival benefit in an exploratory TRG3 subgroup analysis, suggesting a possible role in chemoradiotherapy-resistant disease. The highest pCR occurred in a phase II trial of intra-arterial tislelizumab plus TACE in mismatch repair-proficient LARC, with no grade 3-4 immune-related adverse events. Major complications were uncommon. TACE may improve pathological response with an acceptable safety profile in LARC, although comparative evidence is limited and non-randomized; CIETAI provides first-in-human proof-of-concept for intra-arterial delivery of immunotherapy.

    2026
    引用
    AI阅读
    加入学术空间
    3Early Real-World Experience with Nirogacestat in Patients with Symptomatic Desmoid Tumours-A Single-Centre Review
    L. Fitzpatrick, V Bhadri, S. Collins, P. Grimison, M. Strach
    2026
    引用
    AI阅读
    加入学术空间
    4Outcomes and Determinants of Planned Versus Unplanned Excision in Soft Tissue Sarcoma
    M. Crebert, J. Cockburn, T. Arogundade, M. Le, A. Nguyen, D. Franks, R. Boyle, M. Guzman, D. Steffens
    2026
    引用
    AI阅读
    加入学术空间
    5Combination Doxorubicin and Trabectedin with Trabectedin Maintenance for Advanced Leiomyosarcoma: Preliminary Comparison of Real-World Experience to Pivotal Clinical Trial Results
    S. Collins, L. Fitzpatrick, M. Harrison, T. Scheinberg, M. Strach, V Bhadri, P. Grimison
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 169012 篇论文

    高被引作者

    作者引用发文
    Gabriel N. Hortobagyi52013369
    Eric Van Cutsem51854483
    Eric Winer43386362
    Norman Wolmark40949215
    Michael Atkins38713247
    Richard I. Fisher37255113
    Somerfield Mark R3606684
    José Baselga33828213
    John M. Kirkwood33743196
    Hagop M. Kantarjian33294550

    高产作者

    作者引用发文
    Toni Choueiri21896612
    Heinz-Josef Lenz21616601
    Hagop M. Kantarjian33294550
    Eric Van Cutsem51854483
    Robert J. Motzer32410464
    Neeraj Agarwal6595463
    Josep Tabernero23043409
    Sumanta Kumar Pal7443403
    Jorge Cortes21357392
    Hope S. Rugo21423379

    相关期刊

    Acta oncologica
    American journal of clinical oncology
    Cancer investigation
    Japanese journal of clinical oncology
    Tumori
    Expert review of anticancer therapy
    Cancer reports
    Cancer Research and Treatment
    Cancer Treatment and Research Communications
    ONCOLOGY